Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing discloses a specific transaction on June 22, 2015, involving an increase in the notional allocation of GSK American Depositary Shares (ADSs) within the GSK 401K plan. This increase resulted from the revaluation of the cash element of the notional investment held within the plan.
- Transaction Date: June 22, 2015
- Price per ADS: $43.45
- Connected Person: Dr K Slaoui (connected person of Dr M Slaoui)
- Number of ADSs: 5
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Key Facts for Investor Verification
- Verify the identity of Dr K Slaoui as a connected person of Dr M Slaoui.
- Confirm the impact of the 401K plan revaluation on the notional allocation of ADSs.
- Note that this filing does not contain financial performance data for the period.